Appendix

About UK Fetal Medicine Foundation (FMF)’s triple test

The FMF triple test for early prediction of preterm preeclampsia was co-developed by Professor Liona Poon of The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine’s Department of Obstetrics and Gynaecology and the UK Fetal Medicine Foundation in 2009, and further enhanced in sensitivity and accuracy in 2012. The test has been endorsed by the International Federation of Gynecology and Obstetrics (FIGO). It uses Bayes’ theorem to combine maternal factors with measurements of mean arterial pressure, uterine artery pulsatility index (UtA-PI) and serum placental growth factor (PIGF) to assess individual risks of preterm preeclampsia. Pregnant women can be screened for preterm preeclampsia during the first trimester (weeks 11-13) of pregnancy. The test has been validated in a number of countries in Asia, Australia and Europe, and the US.